# BNB Standard Corp: financial statements, quarterly

BNC · Nasdaq · CIK 1482541 · [Financials](/sectors/financials.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/bnc.md) · [Financials](/companies/bnc/financials.md) · [Filings](/companies/bnc/filings.md) · [Insiders](/companies/bnc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bnc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-07-31) | Q3 FY2024 (2024-09-30) | period not labelled (2024-10-31) | Q4 FY2024 (2024-12-31) | period not labelled (2025-01-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3 d](/filings/0001641172-25-021042.md) | [0.2](/filings/0001641172-25-010831.md) | [1.8](/filings/0001493152-24-032140.md) | [7.0](/filings/0001493152-25-014503.md) | [0.4](/filings/0001493152-24-045783.md) | [7.4](/filings/0001493152-26-029788.md) | [0.4 d](/filings/0001641172-25-021042.md) | [6.9](/filings/0001493152-26-029789.md) | [0.7](/filings/0001641172-25-010831.md) | [7.1](/filings/0001493152-26-029788.md) | [7.3](/filings/0001493152-26-029789.md) | [7.2](/filings/0001482541-26-000051.md) |
| Cost of revenue | $m | [0.5 d](/filings/0001641172-25-021042.md) | [0.4](/filings/0001641172-25-010831.md) | [1.6](/filings/0001493152-24-032140.md) | not reported | [0.5](/filings/0001493152-24-045783.md) | [4.6](/filings/0001493152-26-029788.md) | [0.6 d](/filings/0001641172-25-021042.md) | [5.1](/filings/0001493152-26-029789.md) | [0.7](/filings/0001641172-25-010831.md) | [5.1](/filings/0001493152-26-029788.md) | [5.6](/filings/0001493152-26-029789.md) | [5.2](/filings/0001482541-26-000051.md) |
| Gross profit | $m | [(0.3) d](/filings/0001641172-25-021042.md) | [(0.2)](/filings/0001641172-25-010831.md) | [0.2](/filings/0001493152-24-032140.md) | not reported | [(0.1)](/filings/0001493152-24-045783.md) | not reported | [(0.2) d](/filings/0001641172-25-021042.md) | not reported | [0.0](/filings/0001641172-25-010831.md) | [2.1](/filings/0001493152-26-029788.md) | [1.8](/filings/0001493152-26-029789.md) | [2.0](/filings/0001482541-26-000051.md) |
| Research and development | $m | [0.0 d](/filings/0001641172-25-021042.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [0.7 d](/filings/0001641172-25-021042.md) | [0.8](/filings/0001641172-25-010831.md) | [0.7](/filings/0001493152-24-032140.md) | not reported | [0.7](/filings/0001493152-24-045783.md) | not reported | [0.8 d](/filings/0001641172-25-021042.md) | not reported | [1.1](/filings/0001641172-25-010831.md) | [21.7](/filings/0001493152-26-029788.md) | [6.0](/filings/0001493152-26-029789.md) | [5.4](/filings/0001482541-26-000051.md) |
| Operating income | $m | [(1.0) d](/filings/0001641172-25-021042.md) | [(0.9)](/filings/0001641172-25-010831.md) | [(0.5)](/filings/0001493152-24-032140.md) | not reported | [(0.7)](/filings/0001493152-24-045783.md) | not reported | [(1.0) d](/filings/0001641172-25-021042.md) | not reported | [(1.1)](/filings/0001641172-25-010831.md) | [89.8](/filings/0001493152-26-029788.md) | [(164)](/filings/0001493152-26-029789.md) | [(21.2)](/filings/0001482541-26-000051.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [18.2](/filings/0001493152-26-029788.md) | [(18.4)](/filings/0001493152-26-029789.md) | [0.1](/filings/0001482541-26-000051.md) |
| Net income | $m | [(1.0) d](/filings/0001641172-25-021042.md) | [(0.9)](/filings/0001641172-25-010831.md) | [(0.5)](/filings/0001493152-24-032140.md) | not reported | [(0.7)](/filings/0001493152-24-045783.md) | not reported | [(1.0) d](/filings/0001641172-25-021042.md) | not reported | [(1.1)](/filings/0001641172-25-010831.md) | [284](/filings/0001493152-26-029788.md) | [(107)](/filings/0001493152-26-029789.md) | [(11.4)](/filings/0001482541-26-000051.md) |
| Diluted EPS | $ per share | not reported | [(1.34)](/filings/0001641172-25-010831.md) | [(0.66)](/filings/0001493152-24-032140.md) | not reported | [(0.94)](/filings/0001493152-24-045783.md) | not reported | not reported | not reported | [(1.33)](/filings/0001641172-25-010831.md) | [5.15](/filings/0001493152-26-029788.md) | [(1.92)](/filings/0001493152-26-029789.md) | [(0.22)](/filings/0001482541-26-000051.md) |
| Basic EPS | $ per share | not reported | [(1.34)](/filings/0001641172-25-010831.md) | [(0.66)](/filings/0001493152-24-032140.md) | not reported | [(0.94)](/filings/0001493152-24-045783.md) | not reported | not reported | not reported | [(1.33)](/filings/0001641172-25-010831.md) | [5.18](/filings/0001493152-26-029788.md) | [(1.92)](/filings/0001493152-26-029789.md) | [(0.22)](/filings/0001482541-26-000051.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | period not labelled (2025-01-31) | Q1 FY2025 (2025-03-31) | FY2025 (2025-04-30) | period not labelled (2025-06-06) | Q1 FY2025 (2025-07-31) | Q2 FY2025 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.3](/filings/0001493152-24-032140.md) | [10.3](/filings/0001493152-24-045783.md) | [9.5](/filings/0001641172-25-021042.md) | not reported | [8.7](/filings/0001641172-25-010831.md) | [2.1](/filings/0001482541-26-000019.md) | not reported | [3.0](/filings/0001493152-25-014503.md) | [32.5](/filings/0001493152-26-029788.md) | [11.3](/filings/0001493152-26-029789.md) | [3.1](/filings/0001482541-26-000051.md) | [7.1](/filings/0001482541-26-000051.md) |
| Current assets | $m | [12.2](/filings/0001493152-24-032140.md) | [11.0](/filings/0001493152-24-045783.md) | [10.1](/filings/0001641172-25-021042.md) | not reported | [9.2](/filings/0001641172-25-010831.md) | [10.2](/filings/0001641172-25-021042.md) | not reported | [7.3](/filings/0001493152-25-014503.md) | [58.1](/filings/0001493152-26-029788.md) | [22.5](/filings/0001493152-26-029789.md) | [10.2](/filings/0001482541-26-000051.md) | [14.8](/filings/0001482541-26-000051.md) |
| Total assets | $m | [12.6](/filings/0001493152-24-032140.md) | [11.3](/filings/0001493152-24-045783.md) | [10.4](/filings/0001641172-25-021042.md) | [8.3](/filings/0001493152-26-029789.md) | [9.4](/filings/0001641172-25-010831.md) | [9.0](/filings/0001482541-26-000019.md) | [9.2](/filings/0001482541-26-000051.md) | [19.1](/filings/0001482541-26-000051.md) | [616](/filings/0001493152-26-029788.md) | [437](/filings/0001493152-26-029789.md) | [338](/filings/0001482541-26-000051.md) | [327](/filings/0001482541-26-000051.md) |
| Current liabilities | $m | [1.4](/filings/0001493152-24-032140.md) | [1.0](/filings/0001493152-24-045783.md) | [1.0](/filings/0001641172-25-021042.md) | not reported | [1.1](/filings/0001641172-25-010831.md) | [2.4](/filings/0001641172-25-021042.md) | not reported | [8.3](/filings/0001493152-25-014503.md) | [11.2](/filings/0001493152-26-029788.md) | [8.6](/filings/0001493152-26-029789.md) | [8.6](/filings/0001482541-26-000051.md) | [24.1](/filings/0001482541-26-000051.md) |
| Total liabilities | $m | [1.6](/filings/0001493152-24-032140.md) | [1.1](/filings/0001493152-24-045783.md) | [1.2](/filings/0001641172-25-021042.md) | not reported | [1.2](/filings/0001641172-25-010831.md) | [2.5](/filings/0001641172-25-021042.md) | not reported | [12.2](/filings/0001493152-25-014503.md) | [132](/filings/0001493152-26-029788.md) | [71.9](/filings/0001493152-26-029789.md) | [33.1](/filings/0001482541-26-000051.md) | [37.7](/filings/0001482541-26-000051.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.8](/filings/0001482541-26-000051.md) | [16.8](/filings/0001482541-26-000051.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [10.9](/filings/0001493152-24-045783.md) | [10.2](/filings/0001493152-24-045783.md) | [9.2](/filings/0001641172-25-021042.md) | not reported | [8.2](/filings/0001641172-25-010831.md) | [7.9](/filings/0001641172-25-021042.md) | [7.8](/filings/0001482541-26-000051.md) | [6.9](/filings/0001482541-26-000051.md) | [485](/filings/0001493152-26-029789.md) | [365](/filings/0001493152-26-029789.md) | [305](/filings/0001482541-26-000051.md) | [289](/filings/0001482541-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [489 d](/filings/0001493152-23-041025.md) | [(2,446) d](/filings/0001493152-24-011974.md) | [(2,689)](/filings/0001493152-24-019229.md) | [(1,751) d](/filings/0001493152-24-032140.md) | [(855) d](/filings/0001493152-24-045783.md) | [(835) d](/filings/0001641172-25-021042.md) | [(909)](/filings/0001641172-25-010831.md) | [(273) d](/filings/0001493152-24-032140.md) | [(1,030) d](/filings/0001493152-24-045783.md) | [(842) d](/filings/0001641172-25-021042.md) | [(745)](/filings/0001641172-25-010831.md) | [(6,475)](/filings/0001482541-26-000051.md) |
| Capital expenditure | $k | [16.4 d](/filings/0001493152-23-041025.md) | [0.0 d](/filings/0001493152-24-011974.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [123](/filings/0001482541-26-000051.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [4,279](/filings/0001482541-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.8](/filings/0001493152-23-028379.md) | [8.0](/filings/0001493152-23-041025.md) | [8.1](/filings/0001493152-24-019229.md) | [0.7](/filings/0001493152-24-032140.md) | [0.7](/filings/0001493152-24-045783.md) | [0.7](/filings/0001641172-25-010831.md) | [0.7](/filings/0001493152-24-032140.md) | [0.8](/filings/0001493152-24-045783.md) | [0.8](/filings/0001641172-25-010831.md) | [55.1](/filings/0001493152-26-029788.md) | [55.6](/filings/0001493152-26-029789.md) | [52.9](/filings/0001482541-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,173,850 at 2026-09-04, from the cover of the [10-Q filed 2026-09-11](/filings/0001482541-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.